Risk Factors Update Summary

• Renovaro reported a net loss of $80,650,172 for 2024, up from $39,684,056 in 2023. This change might result in increased investor concern regarding financial stability.
• Renovaro Cube's full-time employees increased from 12 to 25, indicating significant growth in workforce capacity.
• Renovaro Cube's management may need to divert attention from daily activities to manage growth. This could impact operational efficiency significantly.
• The accumulated deficit increased to $325 million in 2024 from $244 million in 2023, indicating worsening financial health.
• New regulatory frameworks for AI in the EU could impose fines of up to 6% of worldwide annual turnover, significantly impacting financial operations.
• Renovaro Cube's ability to attract and retain qualified personnel is critical, as competition for talent is intense in the healthcare technology sector.
• Renovaro Cube's future financial performance depends on effectively managing growth since its independence in 2018. This uncertainty could hinder commercialization efforts.
• Renovaro Cube's business is subject to numerous international risks, including political instability and economic weakness, which could adversely affect operations and profitability.
• Renovaro Cube has never generated revenue from its cancer diagnostics AI platform, raising significant investor risk.
• Management turnover has created uncertainties, potentially harming business execution and financial stability due to loss of institutional knowledge.
• The need for compliance with evolving AI regulations may require substantial resources, increasing operating expenses and affecting financial condition.
• Misconduct by employees or contractors could lead to significant regulatory liabilities, increasing compliance costs. This change might result in substantial financial penalties.
• The company expects significant additional capital will be needed in the future to continue operations. This could lead to dilution of existing stockholders' ownership.
• The company anticipates ongoing significant expenses and operating losses for the foreseeable future, impacting investor confidence.
• Renovaro Cube's ability to generate revenue depends on successful commercialization of its products, which remains uncertain.